Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06536491
PHASE1/PHASE2

EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema

Sponsor: Eclipse Life Sciences, Inc.

View on ClinicalTrials.gov

Summary

This is a prospective, randomized, subject- and evaluator-masked, Phase 2, multicenter study comparing the safety and efficacy of EC-104-6M high-dose (fluocinolone acetonide \[FA\] 0.14 mg) implant and EC-104-4M low-dose (FA 0.092 mg) implant to Ozurdex® (dexamethasone intravitreal (IVT) implant, 0.7 mg) in subjects with diabetic retinopathy (DR) and center-involving diabetic macular edema (DME), with prior suboptimal clinical response to IVT anti-VEGF therapy who have been previously treated with locally administered corticosteroids without a clinically significant rise in intraocular pressure (IOP).

Official title: A Randomized, Controlled, Subject- and Evaluator-Masked, Phase 2 Clinical Trial Comparing EC-104 Intravitreal Implant to Ozurdex® for the Treatment of Diabetic Macular Edema (BETTIS-1)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

75

Start Date

2024-08-19

Completion Date

2025-12-31

Last Updated

2025-01-22

Healthy Volunteers

No

Interventions

DRUG

EC-104 high dose

Intravitreal injection

DRUG

EC-104 low dose

Intravitreal injection

DRUG

Dexamethasone intravitreal implant

Marketed product intravitreal injection

Locations (1)

Retina Associates of Florida, LLC

Tampa, Florida, United States